Intellia Reports Phase 3 Data for Lonvo-Z in Hereditary Angioedema

Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, achieving 87% reduction in attacks versus placebo with 62% of patients attack-free. The in vivo CRISPR gene editing therapy results were published in NEJM and could support a potential regulatory submission.